Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant

J Int Adv Otol. 2018 Apr;14(1):144-147. doi: 10.5152/iao.2018.4517.

Abstract

Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids. Here, we report a case of intractable otitis media due to EOM. Otorrhea was controlled with topical steroids. Bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies (omalizumab). An implantable bone conduction hearing aid was used for rehabilitation of conductive hearing loss.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Bone Conduction / physiology*
  • Bone-Anchored Prosthesis / adverse effects
  • Ear, Middle / drug effects*
  • Ear, Middle / immunology
  • Ear, Middle / pathology
  • Eosinophilia / physiopathology
  • Eosinophils / immunology
  • Female
  • Hearing Aids / adverse effects
  • Hearing Loss / etiology
  • Humans
  • Immunologic Factors / therapeutic use
  • Middle Aged
  • Otitis Media with Effusion / complications
  • Otitis Media with Effusion / drug therapy*
  • Otitis Media with Effusion / immunology
  • Treatment Outcome

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Immunologic Factors
  • anti-IgE antibodies